Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond
Yue Zhong, Fanglian Chi, Hanyu Wu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 231, pp. 114142-114142
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
Claudia J. Diehl, Alessio Ciulli
Chemical Society Reviews (2022) Vol. 51, Iss. 19, pp. 8216-8257
Open Access | Times Cited: 124
Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic
Janet M. Sasso, Rumiana Tenchov, Dasheng Wang, et al.
Biochemistry (2022) Vol. 62, Iss. 3, pp. 601-623
Open Access | Times Cited: 109
Small-molecule discovery through DNA-encoded libraries
Alexander A. Peterson, David R. Liu
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 9, pp. 699-722
Closed Access | Times Cited: 93
Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation
Mengyang Chang, Feng Gao, Devin S. Pontigon, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 25, pp. 14155-14163
Closed Access | Times Cited: 64
Development of an LC-MS/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies
Thi‐Thao‐Linh Nguyen, Jin Woo Kim, Hae-In Choi, et al.
Molecules (2022) Vol. 27, Iss. 6, pp. 1977-1977
Open Access | Times Cited: 48
Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy
Xin Han, Yi Sun
Cell Reports Physical Science (2022) Vol. 3, Iss. 10, pp. 101062-101062
Open Access | Times Cited: 46
Small-molecule probes from bench to bedside: advancing molecular analysis of drug–target interactions toward precision medicine
Sijun Pan, Aixiang Ding, Yisi Li, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 16, pp. 5706-5743
Closed Access | Times Cited: 31
Hydrophobic tag-based protein degradation: Development, opportunity and challenge
Qindi He, Xiaofei Zhao, Donglin Wu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115741-115741
Closed Access | Times Cited: 25
Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Alessandra Salerno, Francesca Seghetti, Jessica Caciolla, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 14, pp. 9507-9530
Open Access | Times Cited: 30
PROTAC Degraders of Androgen Receptor‐Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration
Ruxuan Wang, Tengjiang Zhong, Qiong Bian, et al.
Small Methods (2022) Vol. 7, Iss. 1
Closed Access | Times Cited: 28
Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities
Pritam Maity, Joydeep Chatterjee, Kiran T. Patil, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3135-3172
Closed Access | Times Cited: 21
Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality
Yang Zhou, Shujing Xu, Nerea López-Carrobles, et al.
Acta Materia Medica (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 12
Discovery of a miniaturized PROTAC with potent activity and high selectivity
Lidong Gong, Ridong Li, Jingjing Gong, et al.
Bioorganic Chemistry (2023) Vol. 136, pp. 106556-106556
Open Access | Times Cited: 11
TACkling Cancer by Targeting Selective Protein Degradation
María del Mar Noblejas‐López, David Tébar-García, Raquel López-Rosa, et al.
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2442-2442
Open Access | Times Cited: 11
Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment
Weijiao Chen, Xujie Zhuang, Yuanyuan Chen, et al.
Chinese Journal of Natural Medicines (2025) Vol. 23, Iss. 3, pp. 286-298
Closed Access
Discovery of Novel SHP2 ATTEC Degraders against Pancreatic Ductal Adenocarcinoma Harboring KRAS(G12D) Mutations
Yue Zhong, Yan Lü, Jiahui Li, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Building bioorthogonal click-release capable artificial receptors on cancer cell surface for imaging, drug targeting and delivery
Jing Chen, Peng Ji, Giri Gnawali, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 6, pp. 2736-2746
Open Access | Times Cited: 16
Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
T. N. Rekha, Dongyun Shin
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5190-5190
Open Access | Times Cited: 10
Identification of a Sonically Activated Degrader of Methionine Adenosyltransferase 2A by an in Silico Approach Assisted with the Hole–Electron Analysis
Huan He, Ziwei Wang, Xueke Peng, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 1, pp. 543-554
Closed Access | Times Cited: 3
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions
Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1089-1115
Open Access | Times Cited: 3
CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, et al.
Chemical Biology & Drug Design (2024) Vol. 104, Iss. 5
Open Access | Times Cited: 3
Advancement of Targeted Protein Degradation Strategies As Therapeutics for Undruggable Disease Targets
K Mayuri, Sarojini Sreeraman, Chaitanya Sree Somala, et al.
Future Medicinal Chemistry (2023) Vol. 15, Iss. 10, pp. 867-883
Closed Access | Times Cited: 8
Small-Molecule PROTACs for Cancer Immunotherapy
Zefan Liu, Yajun Zhang, Yucheng Xiang, et al.
Molecules (2022) Vol. 27, Iss. 17, pp. 5439-5439
Open Access | Times Cited: 14
Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
Arvind Negi, Kavindra Kumar Kesari, Anne Sophie Voisin‐Chiret
Pharmaceutics (2022) Vol. 14, Iss. 11, pp. 2523-2523
Open Access | Times Cited: 13
Hearing loss drug discovery and medicinal chemistry: Current status, challenges, and opportunities
Rick Cousins
Progress in medicinal chemistry (2022), pp. 1-91
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top